哺乳動物標靶的雷帕黴素（Mtor）抑制劑治療子宮內膜癌的檢視

The role of mTOR inhibitors for endometrial cancer

早期子宮內膜癌多採手術或輔以放射線治療，預後良好，但在晚期、復發性的患者則不易以手術、化學、放射線或合併治療達到效果，因此須尋求其它輔助方式。由於分子醫學的進步，證實子宮內膜癌是因多分子產生改變所致，其中以phosphoinositide 3-kinase/activating kinase/ mechanisitc(mammalian) target of rapamycin(PI3K/AKT/mTOR) 之途徑被活化，導致細胞的增殖、分裂和新血管生長，最後成為惡性病灶。根據最近研究顯示，以哺乳動物標靶的雷帕黴素抑制劑作為標靶治療的初步效果良好，但仍需更多大型的研究加以證實，冀望在mTOR抑制劑合併荷爾蒙、化學治療或其他藥物，更有助於療效。

Women with early stage endometrial cancer have a relatively good prognosis with surgery alone or surgery plus radiation. However, those patients with advanced or recurrent disease are unlikely to be cured by surgery, conventional chemotherapy, radiation or a combination of these modalities. Targeted therapy is a promising strategy when molecular alterations of endometrial cancer are becoming more understandable. Endometrial carcinomas exhibit distinct molecular alterations which hold potential targets. The phosphoinositide 3-kinase/ activating kinase/mechanisitc (mammalian) target of rapamycin (PI3K/AKT/ mTOR) pathway is the most frequently altered signaling pathway in endometrial carcinoma. Recently, mTOR inhibitors, including temsirolimus, everolimus, and ridaforolimus have shown therapeutic efficacy alone or in combination therapy with other agents in endometrial cancer.